# OnCo record vascular-tumours (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/vascular-tumours/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "vascular-tumours" ;
  schema:name "Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)"@en ;
  schema:alternateName "Childhood vascular tumours"@en, "Angiosarcoma"@en, "EHE"@en, "KHE"@en, "Epithelioid haemangioendothelioma"@en, "Kaposiform haemangioendothelioma"@en ;
  schema:description "Vascular tumours range from angiosarcoma, an aggressive cancer of blood vessel lining cells, to the slow-growing EHE and the infant tumour KHE. Angiosarcoma responds to paclitaxel and, in the sun-damaged scalp form, to immunotherapy; EHE and KHE depend on growth signals that the mTOR blocker sirolimus quiets, and EHE without symptoms is watched."@en ;
  schema:url <https://onco.cc/cancers/vascular-tumours/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Angiosarcoma> ;
  schema:citation <https://www.cancer.gov/types/soft-tissue-sarcoma/patient/child-vascular-tumors-treatment-pdq>, <https://www.cancer.gov/types/soft-tissue-sarcoma>, <https://doi.org/10.1016/j.esmoop.2021.100170>, <https://doi.org/10.1136/jitc-2021-002990> ;
  onco:tag "nci-coverage", "rare", "sarcoma", "paediatric" ;
  onco:related <https://onco.cc/cancers/kaposi-sarcoma/>, <https://onco.cc/cancers/leiomyosarcoma/>, <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/vincristine/> ;
  onco:pathways <https://onco.cc/pathways/hippo-yap/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/vegf-angiogenesis/>, <https://onco.cc/pathways/mutagenesis-signatures/> ;
  onco:terms <https://onco.cc/terms/rare-cancers/> ;
  onco:trials <https://onco.cc/trials/tappas/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-wagner-j-immunother-cancer/> ;
  onco:pipeline <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pazopanib/> ;
  onco:standardOfCare <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/drugs/vincristine/> .